Bloomberg Technology
@bloombergtech·728K subscribers·13.9K videos
Moderna Vaccine Had Decade Head Start Over Pfizer: Chairman
Posted
November 16, 2020
Views
37,224
Likes
375
Comments
551
Engagement
November 16, 2020
37,224
375
551
2.49%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
28:23Now PlayingNov.16 -- Moderna Inc. reported its Covid-19 vaccine was 94.5% effective in a preliminary analysis of a large late-stage clinical trial. Noubar Afeyan, Moderna co-founder and chairman, discusses the company's new data, distribution, plan for emergency use authorization and its advantage over a vaccine by Pfizer Inc. Afeyan spoke with Bloomberg's Emily Chang.
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
